TG Therapeutics Class Action Lawsuit TGTX | Deadline September 16, 2022

Announcement! The TGTX Lawsuit is open to all investors who purchased or otherwise acquired TG Therapeutics Inc. (TG Therapeutics Class Action Lawsuit) securities between January 15, 2020, and May 31, 2022.

CLICK HERE FOR MORE INFORMATION ON THE TGTX CLASS ACTION LAWSUIT

According to the TGTX lawsuit, the defendants allegedly made the following claims during the Class Period and/or omitted to disclose them:

(i) Clinical trials on the Company’s therapeutic product candidates, ubituximab and umbralisib, found serious issues with the benefit-risk ratio and overall survival data;

(ii) Consequently, it seemed improbable that the Company would succeed in getting U.S. permission. the Food and Drug Administration for the Ublituximab relapsing forms of multiple sclerosis Biologics License Application, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, and the Ublilisib marginal zone lymphoma and follicular lymphoma New Drug Application in their present forms;

(iii) Consequently, the Company greatly overestimated the clinical and/or business prospects for ubituximab and umbralisib; and

(iv) As a result, at all pertinent times, the Company’s public statements were materially false and misleading.

If you suffered a loss in TGTX Lawsuit, you have until September 16, 2022, to request that the Court appoint you as the lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.